Showing posts with label Marqibo. Show all posts
Showing posts with label Marqibo. Show all posts

Thursday, February 4, 2016

Marqibo now available to leukemia patients through myTomorrows' Internet-based platform

myTomorrows (Amsterdam, the Netherlands), announced today that it has started a collaboration with Spectrum Pharmaceuticals, Inc. (Henderson, USA; NasdaqGS: SPPI) to provide access to its liposome-encapsulated vincristine for treatment of Philadelphia chromosome negative acute lymphoblastic leukemia.

In August 2012, the US FDA approved the product for treatment of this rare type of leukemia. Through myTomorrows' Internet-based platform, the product is now also made available to patients and doctors in all other countries of the world, except China, Taiwan and Hong Kong, through an Early Access Program.

Marqibo® (vinCRIStine sulfate LIPOSOME injection) Structural Formula Illustration


"We are pleased to make Marqibo® also available to leukemia patients outside of the United States, in countries where the treatment did not yet receive market approval," said Dr. Ronald Brus MD, founder and CEO of myTomorrows. "By taking care of the complex and time consuming process of receiving approval from regulatory authorities and healthcare insurers for individual patients, we aim to unburden these patients and their physicians by fulfilling their request as quickly as possible."


Joseph Turgeon, President and COO of Spectrum Pharmaceuticals said "We look forward to expand our collaboration with myTomorrows to also bring this product to doctors and patients through myTomorrows' global platform. It provides an additional option for acute lymphoblastic leukemia patients whose disease is unresponsive to available therapies and underscores Spectrum's efforts to combat this terrible disease."